ShareValue scores for 688806.SHG: Valuation 50, Quality 41, Growth 60, Health 34.
688806.SHGSSE
Zhuhai Trinomab Pharmaceutical Co., Ltd.
CN¥22.90
(-4.82%)
Updated
688806.SHGSSE
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Updated
Pulse
Pulse
Fundamental Rating
Value Trap Risk
If P/E met sector median
Rating
Trap Risk
P/E to median
Company Details
Zhuhai Trinomab Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, and commercializes therapeutics for infectious diseases and pain-related or autoimmune disorders. The company's product includes Siltartoxatug Injection (TNM002), a recombinant anti-tetanus toxin monoclonal antibody that neutralizes the toxic effects that target the human neural system. The company was founded in 2015 and is based in Zhuhai, China.
Score Analysis
AI Investment Thesis
Zhuhai Trinomab screens as fairly valued versus its sector, with P/B of 192.44 roughly 60 times the 3.2 sector average and P/S of 54.28 about 10 times the 5.3 benchmark, though the market prices two newly launched antibodies rather than current earnings.
The decisive fundamental is profitability: a -256.84% margin against the sector's -0.3% reflects a pre-profit biotech whose first-half 2026 revenue was only CN¥155 million against a CN¥302 million nine-month loss.
The key catalyst was the 15 October 2026 first commercial shipment of RSV antibody Xinduotuo, followed by China's first prescription on 20 October, converting approval into revenue.